

BIBLIOGRAPHY

BIBLIOGRAPHY

- Abramson, C. A., Merck and Co., Inc., Rahway, N. J., personal communication, May 18, 1979.
- Acton, J. P., *Evaluating Public Programs To Save Lives: The Case of Heart Attacks*, Santa Monica, Calif.: RAND Corp., 1973.
- Ahonkhai, V. I., et al., "Failure of Pneumococcal Vaccine in Children With Sickle-Cell Disease," *N.Eng.J. Med.* 301 :26, 1979.
- Ammann, A. J., et al., "Polyvalent Pneumococcal Polysaccharide Immunization of Patients With Sickle-Cell Anemia and Patients With Splenectomy," *N. Eng.J.Med.* 297(17):897, 1977.
- Andersen, R., et al., *Two Decades of Health Services: Social Survey Trends in Use and Expenditure*, Cambridge, Mass.: Ballinger Publishing Co., 1976.
- Applebaum, P. C., et al., "Fatal Pneumococcal Bacteremia in a Vaccinated, Splenectomized Child," *N.Eng.J.Med.* 300:203, 1979.
- Asbury, A., Dept. of Neurology, Univ. of Pennsylvania, Philadelphia, Pa., personal communication, 1978.
- Association of State and Territorial Health Officials—Health Program Reporting System, *Services Expenditures and Programs of State and Territorial Health Agencies: 1974*, Washington, D. C., July 1976.
- Austrian, R., University of Pennsylvania, Philadelphia, Pa., personal communication, June 1979.
- Austrian, R., Addendum to "An Analysis of the Controlled Field Trial of Dodecavalent Pneumococcal Vaccine at the Kaiser Permanence Medical Center, San Francisco, California," report to the National Institute of Allergy and Infectious Diseases, Bethesda, Md., May 28, 1976.
- Austrian, R., "An Analysis of the Controlled Field Trial of Dodecavalent Vaccine at the Kaiser Permanence Medical Center, San Francisco, California," report to the National Institute of Allergy and Infectious Diseases, Bethesda, Md., May 1, 1976.
- Austrian, R., "Interim Summary Contract Progress Report on Project entitled 'Surveillance of Pneumococcal Infection for Field Trials of Polyvalent Pneumococcal Vaccines,' " report to the National Institute of Allergy and Infectious Diseases, Bethesda, Md., 1978.
- Austrian, R., "Pneumococcal Infection," *Prev. Med.* 3:443, 1974.
- Austrian, R., "Random Gleanings From a Life With the Pneumococcus," *J. Infec. Dis.* 131(4):474, 1975.
- Austrian, R., "Report to the Infectious Diseases Advisory Committee, NIAID, on the Pneumococcal Vaccine Program," report to the National Institute of Allergy and Infectious Diseases, Bethesda, Md., Sept. 10, 1971.
- Austrian, R., and J. Gold, "Pneumococcal Bacteremia With Especial Reference to Bacteremic Pneumococcal Pneumonia," *Ann. Intern. Med.* 60:759, 1964.
- Austrian, R., et al., "Prevention of Pneumococcal Infection by Immunization With Capsular Polysaccharides of *Streptococcus pneumoniae*; Current Status of Polyvalent Vaccines," *J. Infec. Dis.* 136(Suppl):538, 1977.
- Austrian, R., et al., "Prevention of Pneumococcal Pneumonia by Vaccination," *Trans. Assoc. Amer. Phys.* 89:185, 1976.
- Ball, R., "National Health Insurance: Comments on Selected Issues," *Science* 200:864, 1978.
- Barrett-Connor, E., "The Nonvalue of Sputum Culture in the Diagnosis of Pneumococcal Pneumonia," *Am. Rev. Resp. Dis.* 103:845, 1971.
- Baynes, T. E., Jr., "Liability for Vaccine-Related Injuries: Public Health Considerations," in *Supplemental Hearings on the President's Proposal To initiate a National Immunization Program To Ensure That Every Citizen May Be Protected Against the Swine Influenza*. Hearings before

- the Subcommittee on Health and Environment, Committee on Interstate and Foreign Commerce, U.S. House of Representatives, 94th Cong., 2d sess., 1976.
- Beck, W., Merck Sharp and Dohme, West Point, Pa., personal communication, August 1978.
- Belcher, J. C., "Acceptance of the Salk Polio Vaccine, " *Rural Soc.* 23:158, 1958.
- Bentley, D. W., Monroe Community Hospital, Rochester, N. Y., personal communication, Aug. 3, 1979.
- Bentley, D. W., "Biological Impact and Economic Consequences of a Pneumococcal Vaccination Program in the Institutionalized Elderly and Chronically Ill., " unpublished manuscript, Rochester, N. Y., n.d.
- Bentley, D. W., et al., "Responses to Pneumococcal Vaccine in Healthy Elderly Volunteers, " *Clin. Res.* 22:436A, 1974.
- Bernstein, P. A., Deputy Director, Human Resources Division, U.S. General Accounting Office, statement before the Subcommittee on Health and Scientific Research, Committee on Human Resources, U.S. Senate, Apr. 6, 1979.
- Blue Cross, Federal Employees Health Benefit Program, data concerning average cost of hospitalization and average length of stay for nonsurgical patients with pneumonia diagnosis.
- Borgoño, J. M., et al., "Vaccination and Revaccination With Polyvalent Pneumococcal Polysaccharide Vaccines in Adults and Infants, " *Proc. Soc. Exp. Med.* 157:148, 1978.
- Broome, C., Center for Disease Control, Atlanta, Ga., personal communication, 1978.
- Buckley, B., Blue Cross/Blue Shield, Chicago, Ill., personal communication, July 1978.
- Bush, J. W., et al., "Health Status Index in Cost Effectiveness: Analysis of PKU Program, " in *Health Status Indexes: Proceedings of a Conference*, edited by R. L. Berg, Chicago: Hospital Research and Educational Trust, 1973.
- Cahill, W., Wyeth Laboratories, Marietta, Pa., personal communication, August 1978.
- California Medical Association, *California Relative Value Studies*, 5th ed., adopted by the California Medical Association Council, San Francisco, Calif., May 10, 1969.
- Chiang, C. L., *Introduction to Stochastic Processes in Biostatistics*, New York: John Wiley and Sons, 1968.
- Chin, J., State Epidemiologist, California Dept. of Health, Berkeley, Calif., personal communication, August 1978.
- Clausen, J. A., et al., "Parent Attitudes Toward Participation of Their Children in Polio Vaccine Trials, " *Am. J. Pub. H.* 44:1526, 1954.
- Cole, R., "Serum Treatment in Type 1 Lobar Pneumonia. " *J. Am. Med. A.* 93:741, 1929.
- Cooper, B. S., and D. P. Rice, "The Economic Cost of Illness Revisited, " *Soc. Sec. Bulletin*, February 1976, p. 21.
- Coulehan, J. L., et al., "Bacterial Meningitis in Navajo Indians, " *Pub. H. Rpts.* 91:404, 1976.
- Davis, D. J., Director, National Institute of Allergy and Infectious Diseases, Bethesda, Md., letter to Director, National Institutes of Health, Apr. 10, 1967.
- Davis v. Wyeth Laboratories*, 399 F. 2d 121 (9th Circuit 1968).
- Deasey, L. C., "Socioeconomic Status and Participation in the Poliomyelitis Vaccine Trials, " *Am. Soc. Rev.* 21 :185, 1956.
- Dixon, J. M. S., "Pneumococcus Resistant to Erythromycin and Lincomycin, " *Lancet*, Mar. 11, 1967, p. 573.
- Dorff, G. J., et al., "Etiologies and Characteristic Features of Pneumonias in a Municipal Hospital, " *Am. J. Med. Sci.* 266(5):349, 1973.
- Dowling, H. F., "The Rise and Fall of Pneumonia Control Programs, " *J. Infec. Dis.* 127(2):201, 1973.

- Eddy, D., *Screening for Cancer: Theory, Analysis, and Design*, Palo Alto, Calif.: Stanford University Press, 1978.
- Eeckels, R., et al., "Abnormal Distribution of Hemoglobin Genotypes in Negro Children With Severe Bacterial Infections, " *Nature* 216:382, 1967.
- Ekwurzel, G. M., et al., "Studies on Immunizing Substances in Pneumococci: VIII Report on Field Tests To Determine the Prophylactic Value of a Pneumococcus Antigen, " *Pub.H.Rpts.* 53:1877, 1938.
- Evans, R. G., "Modeling the Objectives of the Physicians, " paper presented to the Working Symposium of Canadian Health Care Economists, Queens University, Canada, Sept. 5-6, 1974.
- Fairity, R., Blue Cross/Blue Shield, Newark, N. J., personal communication, July 1978.
- Fein, R., *Economics of Mental Illness*, report to the Staff Director, Joint Commission on Mental Illness and Health, Monogr. Series No. 2, New York: Basic Books, Inc., 1958.
- Feiner, B., Office of the General Counsel, U.S. Department of Health, Education, and Welfare, Washington, D. C., personal communication, May 24, 1979.
- Fekety, F. R., Jr., et al., "Bacteria, Viruses, and Mycoplasmas in Acute Pneumonia in Adults, " *Am. Rev. Resp. Dis.* 104:499, 1971.
- Felton, L. D., "Studies on Immunizing Substances in Pneumococci: VII Response in Human Beings to Antigenic Pneumococcus Polysaccharides, Type I and II, " *PI/b. H.Rpts.* 53:1833, 1938.
- Filice, G. A., Stanford University, Palo Alto, Calif., personal communication, June 1979.
- Filice, G. A., et al., "Pneumococcal Bacteremia in Charleston County, S.C., " unpublished manuscript, Atlanta, Ga., n.d.
- Finland, M., "Excursions Into Epidemiology: Selected Studies During the Past Four Decades at Boston City Hospital, " *J.Infec.Dis.* 128(1):76, 1973.
- Finland, M., and M. W. Barnes, "Changes in Occurrence of Capsular Serotypes of *Streptococcus pneumoniae* at Boston City Hospital During Selected Years Between 1935 and 1974, " *J.Clin. Microb.* 5:154, 1977.
- Fiumara, N. J., and G. E. Waterman, "Statewide Geriatric Immunization Program With Poly-valent Pneumococcal Vaccine (Pneumovax), " *Curr.Ther.Res.* 25:185, 1979.
- Fey, H. M., et al., "Pneumococcal Isolations From Patients With Pneumonia and Control Subjects in a Prepaid Medical Care Group, " *Am.Rev.Resp.Dis.* 3:595, 1975.
- Francis, D. P., et al., "Measles Control in Oregon, " *Pub. H.Rpts.* 93:216, 1978.
- Francis, T., and W. S. Tillett, "Cutaneous Reactions in Pneumonia: The Development of Antibodies Following the Intradermal Injection of Type-Specific Polysaccharides, " *J.Exper.Med.* 52:573, 1930.
- Fraser, D. W., Center for Disease Control, Atlanta, Ga., personal communication, June 1979.
- Fraser, D. W., et al., "Bacterial Meningitis in Bernalillo County, New Mexico: A Comparison With Three Other American Populations, " *Am. J.Epidem.* 100(1):29, 1974.
- Fraser, D. W., et al., "Risk Factors in Bacterial Meningitis: Charleston County, South Carolina, " *J.Infec.Dis.* 127:271, 1973.
- Fuchs, V. R., *Who Shall Live?* New York: Basic Books, 1974.
- Gaston, M., National Sickle-Cell Program, National Institutes of Health, Bethesda, Md., personal communication, June 1978.
- Gibson, R. M., et al., "Age Differences in Health Care Spending, FY 1977, " *HCFA Notes*, vol. II, No. 2., Washington, D. C.: U.S. Department of Health, Education, and Welfare, December 1978.
- Giebink, G. S., et al., "Vaccine-Type Pneumococcal Pneumonia After Vaccination in an Asplenic Patient, " *J.Am. Med. A.* 241:2736, 1979.

- Givens v. Lederle, 556 F. 2d 1341 (5th Circuit 1977).
- Glasser, M. A., "A Study of the Public's Acceptance of the Salk Vaccine Program," *Am. J. Pub. H.* 48:141, 1958.
- Grant, M., California State Department of Health, Berkeley, Calif., personal communication, August 1978.
- Green, J., "Physician-Induced Demand for Medical Care," *J. Human Resources* 13(Suppl):21, 1978.
- Grosse, R. N., "Cost-Benefit Analysis of Health Services," *Ann. Am. Acad.* 399:89, 1972.
- Hales, K., and S. L. Barriere, "Polyvalent Pneumococcal Vaccines: A Review," *Am. J. Hosp. Pharm.* 36:773, 1979.
- Hamilton, P. S., Deputy General Counsel, U.S. Department of Health, Education, and Welfare, statement before the Subcommittee on Health and Scientific Research, Committee on Human Resources, U.S. Senate, Apr. 6, 1979.
- Hansman, D., et al., "Pneumococci Insensitive to Penicillin," *Nature* 230:407, 1971.
- Hecht, A., "Making Sure Biological Are Safe," *FDA Consumer*, July/August 1977, p. 21.
- Heffron, R., *Lobar Pneumonia With Special Reference to Pneumococcus Lobar Pneumonia*, New York: Commonwealth Fund, 1939.
- Heffron, R., and E. S. Robinson, "Final Report of the Massachusetts Pneumonia Study and Service, 1931 -1935," *Commonwealth* 24:25, 1937.
- Heidelberger, M., "Persistence of Antibodies in Man After Immunization," in *The Nature and Significance of the Antibody Response*, edited by A. M. Pappenheimer. New York: Columbia Univ. Press, 1953.
- Heidelberger, M., and O. T. Avery, "The Soluble Specific Substance of Pneumococcus," *J. Exper. Med.* 38(1):73, 1923.
- Heidelberger, M., et al., "The Human Antibody Response to Simultaneous Injection of Six Specific Polysaccharides of Pneumococcus," *J. Exper. Med.* 88:369, 1948.
- Hill, J., National Institute of Allergy and Infectious Diseases, Bethesda, Md., personal communication, 1978.
- Hilleman, M. R., Merck Sharp and Dohme, West Point, Pa., personal communication, May 12, 1978.
- Hilleman, M. R., "Research and Development of Vaccines From the Industrial Research Perspective," paper presented at the National Immunization Conference, National Institutes of Health, Bethesda, Md., Nov. 14, 1976.
- Hinman, A. R., Center for Disease Control, Atlanta, Ga., personal communication, August 1978.
- Hinman, A. R., "Resurgence of Measles in New York," *Am. J. Pub. H.* 62:498, 1972.
- Horton, R. E., "Pneumococcal Vaccine Program: Objectives, Guidelines for Implementation, and Current Program Activities," internal report, National Institute of Allergy and Infectious Diseases, Bethesda, Md., 1974.
- "Hospital Indicators," *Hospitals*, May 6, 1978, p. 72.
- Interagency Task Force on Product Liability: Final Report*, (PB-273-220), U.S. Department of Commerce, National Technical Information Service, Washington, D. C., November 1977.
- Jacobs, M. R., et al., "Emergence of Multiply Resistant Pneumococci," *N. Eng. J. Med.* 299:735, 1978.
- Johnson, I., Eli Lilly, Indianapolis, Ind., personal communication, May 18, 1978.
- Jones, D., Health Insurance Institute of America, New York, N. Y., personal communication, July 1978.

- Jordan, W. S., "The Role of Government in Vaccine Research and Development," in *Reports and Recommendations of the National Immunization Work Groups*, report to the Office of the Assistant Secretary for Health, U.S. Department of Health, Education, and Welfare, submitted by JRB Associates, McLean, Va., Mar. 15, **1977**.
- Kaiser, A. B., and W. Schaffner, "Prospectus: The Prevention of Bacteremic Pneumococcal Pneumonia," *J. Am. Med. A.* 230:408, **1974**.
- Kaplan, G.J., et al., "Long-Term Effects of Otitis Media: A Ten-Year Cohort Study of Alaskan Eskimo Children," *Pediatrics* 52:577, **1973**.
- Kasdin, S., Merck Sharp and Dohme, West Point, Pa., personal communication, Aug. 14, 1979.
- Kaufman, P., "Pneumonia and Old Age," *Arch. Intern. Med.* 79:518, **1947**.
- Kavet, J., "A Perspective on the Significance of Pandemic Influenza," *Am. J. Pub. H.* **67(11)**:1063, **1977**.
- Kavet, J., "Influenza and Public Policy," doctoral thesis submitted to School of Public Health, Harvard Univ., Cambridge, Mass., Apr. 17, **1972**.
- Kennedy, D. K., "A Calm Look at Drug Lag," *Am. Med. A.* 239:423, **1978**.
- Kennedy, S., Joint Commission on Prescription Drug Use, Rockville, Md., personal communication, August **1979**.
- Kislak, J. W., "Type 6 Pneumococcus Resistant to Erythromycin and Lincomycin," *N. Eng. J. Med.* 276:852, **1967**.
- Klarman, H. E., "Application of Cost-Benefit Analysis to the Health Services and the Special Case of Technologic Innovation," *Intern. J. Health* 4:325, 1974.
- Klarman, H. E., *The Economics of Health*, New York: Columbia Univ. Press, **1965**.
- Klarman, H. E., "Present Status of Cost-Benefit Analysis in the Health Field," *Am. J. Pub. H.* **57**: 1948, **1967**.
- Klarman, H. E., and D. Guzick, "Economics of Influenza," in *Influenza—Virus, Vaccines, and Strategy: Proceedings of a Working Group on Pandemic Influenza*, edited by P. Selby, New York: Academic Press, **Inc.**, **1976**.
- Klarman, H. E., et al., "Cost-Effectiveness Analysis Applied to the Treatment of Chronic Renal Disease," *Medical Care* 6:48, **1968**.
- Kramer, M. S., et al., "An Algorithm for the Operational Assessment of Adverse Drug Reactions," *J. Am. Med. A.* 242:623, **1979**.
- Krugman, S., "Production and Supply," in *Reports and Recommendations of the National Immunization Work Groups*, report to the Office of the Asst. Sec. for Health, U.S. Department of Health, Education, and Welfare, submitted by JRB Associates, McLean, Va., Mar. 15, 1977.
- Lamontaigne, J., National Institute of Allergy and Infectious Diseases, Bethesda, Md., personal communication, July 1978.
- Lemke, J., "Immunizations and Vaccines: Federal Programs and Policies," Issue Brief No. IB77061, **Washington, 11. C.: Congressional]** Research Service, Library of Congress, October **1977**.
- Lister, F. S., "Prophylactic Inoculation of Man Against Pneumococcal Infections, and More Particularly Against Lobar Pneumonia," *Pub. S. Afr. Inst. Med. Res.* 10:304, 1917.
- Loda, F. A., et al., "Studies on the Role of Viruses, Bacteria and Pneumonia as Causes of Lower Respiratory Tract Infections in Children," *J. Pediatrics* 72(2):161, 1968.
- Luft, H. S., "Why Do HMOs Seem To Provide More Health Maintenance Services?" *Milbank Mem. Fund. Q.* 56:140, **1978**.
- Lund, E., "Distribution of Pneumococcus Types at Different Times in Different Areas," in *Symposium: Bacterial Infections*, edited by M. Finland, et al., Berlin: Springer-Verlag, 1971.
- Lund, E., "Laboratory Diagnosis of Pneumococcus Infections," *Bulletin WHO* 23(1):5, 1960.

- Lutins, T., Health Insurance Institute of America, New York, N. Y., personal communication, July 1978.
- MacLeod, C. M., et al., "Prevention of Pneumococcal Pneumonia by. Immunization With Specific Capsular Polysaccharides," *J.Exper. Med.* 82(6):445, 1945.
- Manton, K., and E. Stollard, Duke University, Center for Demographic Studies, computer program to determine number of deaths with pneumonia mentioned as a cause of death based on data tapes provided by NCHS (U.S. National Center for Health Statistics, Division of Vital Statistics), 1978.
- Mausner, J. S., and A. Bahn, *Epidemiology: An Introductory Text*, Philadelphia: W. B. Saunders co., 1974.
- Maynard, C. D., "Pneumonia Inoculation Experiment No. III, " *Med. J.S. Afr.* 11 :36, 1915.
- Meyer, H. M., "Are Vaccines Endangered Species?" paper presented at the National Immunization Conference, National Institutes of Health, Bethesda, Md., Nov. 13, 1976.
- Minor, D., et al., "Response of Patents With Hodgkin's Disease to Pneumococcal Vaccine, " *Ann. Intern.Med.* 90:887, 1979.
- Mitchner, E., Blue Cross-Blue Shield, Chicago, Ill., personal communication, July 1978.
- Mufson, M. A., et al., "Capsular Types and Outcome of Bacteremic Pneumococcal Disease in the Antibiotic Era, " *Arch. Intern. Med.* 134:505, 1974.
- Neuhauser, D., and A. M. Lewicki, "National Health Insurance and the Sixth Stool Guaiac, " *Policy Analysis* 2:175, 1976.
- Neustadt, R. E., and H. V. Fineberg, *The Swine Flu Affair: Decision-Making on a Slippery Disease*, Washington, D. C.: U.S. Department of Health, Education, and Welfare, 1978.
- Olmsted, R. W., et al., "The Pattern of Hearing Following Acute Otitis Media, " *J. Pediatrics* 65:252, 1964.
- Opinion Research Corporation, *Public Attitudes Toward Immunization: August 1977 Through February 1978*, study for the Center for Disease Control, Atlanta, Ga., submitted by Opinion Research Corporation, Princeton, N. J., June 1978.
- Overturf, G. D., et al., "Death From Type 6 Pneumococcal Septicemia in a Vaccinated Child With Sickle-Cell Disease, " *N.Eng.J. Med.* 300:143, 1979.
- Pantell, R. H., and T. J. Stewart, "The Pneumococcal Vaccine: Immunization at a Crossroad," *J. Am. Med. A.* 241:2272, 1979.
- Parkman, P., Bureau of Biologics, Food and Drug Administration, Bethesda, Md., personal communication, 1979.
- Patrick, D. L., et al., "Toward an Operational Definition of Health, " *J.Health Soc.Behav.* Mar. 14, 1973, p. 6.
- Pearman, W. A., "Participation in Flu Immunization Projects: What Can We Expect in the Future?" *Am. J.Pub.H.* 68:674, 1978.
- Pearson, H. A., Yale University, New Haven, Conn., personal communication, June 1978.
- Pharmaceutical Manufacturers Association, *Prescription Drug Industry Factbook 1976*, Washington, D. C., 1976.
- Pigou, A. C., *The Economics of Welfare*, London: MacMillan, 1932.
- Powars, D. R., "Natural History of Sickle-Cell Disease: The First Ten Years, " *Semi-., Hematol.* 12:667, 1975.
- Preheim, L., and M. Rytel, "Pneumococcal Infection After Vaccination, *Lancet* 2:1317, 1978.
- Prest, A. R., and R. Turvey, "Cost-Benefit Analysis: A Survey, " *Econ. J.* 75(300):683, 1965.
- Price, I. B., "What's Happening to Federally Aided Health Programs Under State Departments of Human Resources?" *Pub. H. Rpts.* 93:221, 1978.

- "The Problems of Insuring Medical Malpractice, " report prepared at the direction of the All Industry Medical Malpractice Insurance Committee by a subcommittee of Aetna Life and Casualty, et al., with the assistance of the American Insurance Association, American Mutual Insurance Alliance and Insurance Services Office, November 1975.
- Relman, A. S., "The Ethics of Randomized Clinical Trials: Two Perspectives, " *N.Eng.J. Med.* 300:1272, 1979.
- Report of the Special Advisory Panel on Medical Malpractice, State of New York*, Albany, N. Y.: State of New York, January 1976.
- Reyes v. Wyeth Laboratories*, 498 F. 2d 1264 (5th Circuit 1974).
- Rice, D., et al., "The Current Burden of Illness in the United States, " paper presented at the annual meeting of the Institute of Medicine, Washington, D. C., Oct. 27, 1976.
- Richmond, J. B., Assistant Secretary for Health, U.S. Department of Health, Education, and Welfare, statement before the Subcommittee on Health and Scientific Research, Committee on Human Resources, U.S. Senate, Feb. 7, 1978.
- Riley, I. D., et al., "Immunisation With a Polyvalent Pneumococcal Vaccine, " *Lancet*, June 25, 1977, p. 1338.
- "A Risky Exodus From Vaccines, " *BusinessWeek*, Apr. 10, 1978, p. 118.
- Robbins, F. C., "The Demand for Human Trials in Biologicals Research, " reprinted by the U.S. Department of Health, Education, and Welfare, Washington, D. C., from *Proceedings of the International Conference on the Role of the Individual and the Community in the Research, Development and Use of Biologicals*, Geneva, Switzerland, Mar. 2-5, 1976.
- Robbins, J. B., Bureau of Biologics, Food and Drug Administration, Bethesda, Md., personal communication, Sept. 6, 1978.
- Robbins, J. B., Bureau of Biologics, Food and Drug Administration, Bethesda, Md., personal communication, July 5, 1979.
- Roberts, J. A., "Economic Evaluations of Health Care: A Survey, " *Brit.J. Prev. Soc. Med.* 28:210, 1974.
- "Rocky Mountain Fever Vaccine: No Maker, " *Medical World News* 19:39, 1978.
- Roden, D. A., and W. G. Platt, "A Study To Estimate the Prevalence and Costs of Pneumonia, " Fairfax, Va.: Pracon Inc., February 1978.
- Roemer, M. I., et al., "Copayments for Ambulatory Care: Penny Wise and Pound Foolish, " *Medical Care* 8:457, 1975.
- Rosenstock, I. M., "Why People Fail To Seek Poliomyelitis Vaccination, " *PI/b. H. Rpts.* 74:98, 1959.
- Rowe, D. S., "Acute Suppurative Otitis Media, " *Pediatrics* 56:285, 1975.
- Schieber, G. J., et al., "Physician Fee Patterns Under Medicare: A Descriptive Analysis, " *N. Eng. J. Med.* 294(20):1089, 1976.
- Schiffman, G., and R. Austrian, "A Radioimmunoassay for the Measurement of Pneumococcal Capsular Antigens and of Antibodies Thereto, " *Federation Proceedings* 30(2):658, 1971.
- Schmeck, H., "Vaccines: Low Profits and High Liability, " *N. Y. Times*, June 19, 1978.
- Schnee, J. E., and E. Caglarcan, "Economic Structure and Performance of the Ethical Pharmaceutical Industry, " in *The Pharmaceutical Industry*, edited by C. Lindsay, New York: John Wiley and Sons, 1978.
- Schoenbaum, S. C., et al., "Benefit-Cost Analysis of Rubella Vaccination Policy, " *N.Eng.J. Med.* 294:306, 1976.
- Schoenbaum, S. C., et al., "The Swine Influenza Decision, " *N.Eng.J. Med.* 295(14):759, 1976.
- Schoenberger, L., Center for Disease Control, Atlanta, Ga., personal communication, June 1978.

- Schoenberger, L., et al., "Guillain-Barre Syndrome Following Vaccination in the National Influenza Immunization Program, U. S., 1976 -77," *Am.J.Epidem.* 110:105, 1979.
- Schweitzer, S. O., and B. R. Luce, *A Cost-Effective Approach to Cervical Cancer Detection*, report to the National Center for Health Services Research, U.S. Department of Health, Education, and Welfare, Washington, D. C., April 1978.
- Scitovsky, A. A., and N. McCall, **Changes in the Costs of Treatment of Selected Illnesses, 1951-1964-1976**, report for the National Center for Health Services Research, U.S. Department of Health, Education, and Welfare, Washington, D. C., 1977.
- Seeler, R. A., et al., "Diplococcus pneumonia Infections in Children With Sickie-Cell Anemia, " *Am.J. Dis. Child*, 123:8, 1972.
- Semel, J. D., et al., "Severe Febrile Reaction to Pneumococcal Vaccine" (letter), *J.Am. Med. A.* 241:1792, 1979.
- Sencer, D. J., and N. W. Axnick, "Cost-Benefit Analysis, " *Symp. Series Immunobiol. Stand.* 22:37, 1973.
- Shapera, R. M., and J. M. Matsen, "Host Factors and Capsular Typing of Body Fluid Isolates in Fulminant Pneumococcal Infections, " *Infection and Immunity* 5:132, 1972.
- Shaw, B., *Tile Doctor's Dilemma*, Baltimore: Penguin Books Inc., 1954.
- Shepard, D., School of Public Health, Harvard University, Cambridge, Mass., personal communication, 1979.
- Shepard, D., and R. Zeckhauser, "The Assessment of Programs To Prolong Life, Recognizing Their Interaction With Risk Factors, " John F. Kennedy School of Government, Public Policy Program, Discussion Paper Series No. 32D, Cambridge, Mass.: Harvard Univ., June 1975.
- Shepard, D., and R. Zeckhauser, "Interventions in Mixed Populations: Concepts and Applications," John F. Kennedy School of Government, Public Policy Program, Discussion Paper Series No. 49D, Cambridge, Mass.: Harvard Univ., December 1977.
- Siber, G. R., et al., "Impaired Antibody Response to Pneumococcal Vaccine After Treatment for Hodgkin's Disease, " *N. Eng. J. Med.* 299:443, 1978.
- Smit, r., et al., "Protective Efficacy of Pneumococcal Polysaccharide Vaccines, " *J.Am. Meal, A.* 238:2613, 1977.
- Smith, G. R., "Liability in Preventive Medicine: A Review and Analysis of Trends, Primarily Those Related to Vaccination Programs, " in *Supplemental Hearings 011 the President's Proposal To Initiate a National Immunization Program To E} isure That Every Citizen May Be Protected Against tile Swine Influenza*. Hearings before the Subcommittee on Health and Environment, Committee on Interstate and Foreign Commerce, U.S. House of Representatives, 94th Cong., 2d sess. , 1976.
- Staats, E., Comptroller General, U.S. General Accounting Office, letter to Chairman, Subcommittee on Energy and Power, and Chairman, Subcommittee on Oversight and Investigations, Committee on Interstate and Foreign Commerce, U.S. House of Representatives, Feb. 6, . 1979.
- Stebbins, E. L., et al., "Prevalence of Pneumococcus Carriers: Specific Types in Epidemic and Nonepidemic Areas, " *Am.J.Pub.H.* 30:349-360, 1940.
- Steiner-, K. C., and H. A. Smith, "Application of Cost-Benefit Analysis to a PKU Screening Program, " *Inquiry* 10:34, 1973.
- Stessel, P., Lederle Laboratories, Pearl River, N. Y., letter to the Office of Technology Assessment, Nov. 13, 1978.
- Strange, I. V., and A. T. Sumner, "Predicting Treatment Costs and Life Expectancy for End-Stage Renal Disease, " *N. Eng. J. Med.* 298(7):372, 1978,
- Sullivan, R. J., et al., "Adult Pneumonia in a General Hospital," *Arch.Intern. Med.* 129:935, 1972.

- Tilghman, R. C., and M. Finland, "Clinical Significance of Bacteremia in Pneumococcal Pneumonia," *Arc./Intern. Med.* 59:602, 1937.
- Timm, E. A., "75 Years Compliance With Biological Product Regulations," paper presented at the Food and Drug Law Institute Meeting, Washington, D. C., Dec. 13, 1977.
- Uhl, G., et al., "Febrile Reactions to Pneumococcal Vaccine," *N. Eng. J. Med.* 299:1318, 1978.
- U.S. Congress, General Accounting Office, *The Swine Flu Program-An Unprecedented Adventure in Preventive Medicine: Report to the Congress by the Comptroller General of the United States*, Washington, D. C., June 27, 1977.
- _____, House Committee on Interstate and Foreign Commerce, *Review and Evaluation of the Swine Flu Immunization Program*. Hearings before the Subcommittee on Health and Environment, 95th Cong., 1st sess., Sept. 16, 1977.
- _____, House Committee on Interstate and Foreign Commerce, *Federal High-Risk Influenza Immunization Initiative - Oversight*. Hearings before the Subcommittee on Health and Environment, 95th Cong., 1st sess., Sept. 16, 1977.
- _____, Office of Technology Assessment, *Assessing the Efficacy and Safety of Medical TPCs* [I] [ologies. Washington, D. C.: U.S. Govt. Print. Of f., September 1978.
- _____, Office of Technology Assessment, *Development of Medical Technology: Opportunities for Assessment*, Washington, D. C.: U.S. Govt. Print. Of f., 1976.
- _____, Office of Technology Assessment, *Policy Implications of the Computed Tomography (CT) Scanner*, Washington, D. C.: U.S. Govt. Print. Off., August 1978.
- U.S. Executive Branch, Bureau of Biologics, Food and Drug Administration, "Summary for Basis of Approval for Pneumococcal Vaccine, Polyvalent (BB Ref. No. 75-49)." Bethesda, Md., 1977.
- _____, Bureau of the Budget, *Standard Industrial Classification Manual*, Washington, D. C.: U.S. Govt. Print. of f., 1967.
- _____, Bureau of the Census, "Projections of the Population of the United States: 1977 to 2050," in *Current Population Reports, Series P-25, No. 704*, Washington, D. C.: U.S. Govt. Print. of f., 1977.
- _____, Bureau of the Census, *1977 Census of Manufacturers*, "Biological Products," preliminary report MC77-1-28C-1 (P), Washington, D. C., June 1979.
- _____, Bureau of the Census, *Statistical Abstract*, Washington, D. C.: U.S. Govt. Print. Of f., 1977.
- _____, Bureau of the Census, unpublished data from the Population Projections Branch concerning mortality rates by single years of age.
- _____, Bureau of Labor Statistics, Consumer Price Index Information Service, August 1979.
- _____, Center for Disease Control, "Fact Sheet on Immunization Initiative," Atlanta, Ga., 1978.
- _____, Center for Disease Control, *Morbidity and Mortality Weekly Report* 26:345, 1977.
- _____, Center for Disease Control, *Morbidity and Mortality Weekly Report* 27:391, 1978.
- _____, Center for Disease Control, *Morbidity and Mortality Weekly Report* 28:225, 1979.
- _____, Center for Disease Control, *United States Immunization Survey: 1975*, Atlanta, Ga., June 1976.
- _____, Center for Disease Control, *United States Immunization Survey: 1976*, Atlanta, Ga., November 1977.
- _____, Department of Health, Education and Welfare, *Liability Arising Out of Immunization Programs: Final Report to Congress*, Washington, D. C., May 1978.
- _____, National Center for Health Statistics, Division of Vital Statistics, unpublished data concerning the number of deaths from pneumonia in 1976, Washington, D.C.

- _____. National Center for Health Statistics, Health Interview Survey, unpublished data concerning the number of pneumonia ambulatory visits and number of pneumonia and total disability days in 1976, Washington, D.C.
- _____. National Center for Health Statistics, Hospital Discharge Survey, unpublished data concerning the number of hospital discharges and days with pneumonia as a diagnosis in 1976, Washington, D.C.
- _____. National Center for Health Statistics, National Ambulatory Medical Care Survey, unpublished data concerning the number of pneumonia office visits in 1976, Washington, D.C.
- _____. National Center for Health Statistics, National Nursing Home Survey, unpublished data concerning residents in nursing and personal care homes in 1977, Washington, D.C.
- _____. National Institute of Allergy and Infectious Diseases, Minutes of the meeting of the Ad Hoc Pneumococcal Vaccine Committee, Bethesda, Md., Apr. 22, 1970.
- _____. Public Health Service, *Annual Report of the Surgeon General of the Public Health Service of the United States for the Fiscal Year 1941*, Washington, D. C.: U.S. Govt. Print. Of f., 1941.
- U.S. Executive Office of the President, Office of Management and Budget, "Circular No. A-94 (revised)," Washington, D. C., Mar. 27, 1971.
- Valenti, W. M., et al., "Type-Specific Pneumococcal Respiratory Disease in the Elderly and Chronically 111," *Am. Rev. Resp. Dis.* 117:233, 1978.
- Wan, T. T. H., and B. Livieratos, "Interpreting a General Index of Subjective Well-Being, " *Milbank Mere. Fund Q.* 56(2):187, 1978.
- Wardell, W. M., cd., *Controlling the Use of Therapeutic Drugs: An International Comparison*, Washington, D. C.: American Enterprise Institute, 1978.
- Weibel, R. E., et al., "Studies in Human Subjects of Polyvalent Pneumococcal Vaccines (39894)," *Proc. Soc. Exp. Biol. Med.* 156:144, 1977.
- Weinstein, M. C., and W. B. Stason, "Foundations of Cost-Effectiveness Analysis for Health and Medical Practices, " *N. Eng. J. Med.* 296(13):716, 1977.
- Weinstein, M. C., and W. B. Stason, *Hypertension: A Policy Perspective*, Cambridge, Mass.: Harvard Univ. Press., 1976.
- Weisbrod, B. A., *Economics of Public Health*, Philadelphia: Univ. of Pennsylvania Press, 1961.
- Welsh, J. S., "Target: Adverse Drug Reactions, " *Amer. Pharmacy*, NS19:30, 1979.
- White, B., *The Biology of the Pneumococcus*, New York: Commonwealth Fund, 1938.
- Wildavsky, A., "The Political Economy of Efficiency: Cost-Benefit Analysis, Systems Analysis, and Program Budgeting, " *Pub. Admin. R.* December 1966, p. 292.
- Wright, A. E., "Prophylactic Inoculation Against Pneumococcus Infections and on the Results Which Have Been Achieved by It, " *Lancet* 87, 1914.
- Zeckhauser, R., and D. Shepard, "Where Now for Saving Lives?" *Law and Contemporary Problems* 40(4):11, 1976.
- Zelen, M., "A New Design for Randomized Clinical Trials, " *N. Eng. J. Med.* 300:1242, 1979.